Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in …

Apr 2, 2024 · Ozempic was already available for lowering the risk of major adverse cardiovascular events in patients with diabetes who have established cardiovascular disease and have …

Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events (MACE; defined as CV death, non-fatal …

Nov 10, 2016 · We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for …

Nov 16, 2023 · Semaglutide, the compound on which weight-loss drugs Ozempic and Wegovy are based, significantly reduced the number of cardiac events in people without diabetes in a large …

Sep 20, 2024 · GLP-1 drugs like Ozempic and Wegovy may help reduce the risk of cardiovascular disease and prevent more than 34,000 heart attacks and strokes a year.

Nov 16, 2023 · New research presented at the American Heart Association Scientific Sessions indicates that semaglutide, the active ingredient in Ozempic and Wegovy, has significant …

Learn more about the cardiovascular benefit of Ozempic® (semaglutide) injection and prescribing to your adult patients with T2D and established CVD. Read Important Safety and Prescribing …

Semaglutide, the molecule found in Ozempic, Rybelsus, and Wegovy, surged into the public eye boasting impressive claims of enhanced diabetes control, weight loss, and a reduced risk of …

Jan 16, 2020 · In the 2-year SUSTAIN 6 trial, Ozempic ® significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal …